Statin Intolerance-An Asian Perspective.
作者信息
Tomlinson Brian, Chan Paul, Liu Zhong-Min
机构信息
Research Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine.
Faculty of Medicine, Macau University of Science and Technology.
出版信息
J Atheroscler Thromb. 2020 May 1;27(5):485-488. doi: 10.5551/jat.50435. Epub 2019 Sep 25.
Abstract
摘要
相似文献
1
Statin Intolerance-An Asian Perspective.他汀不耐受——亚洲视角
J Atheroscler Thromb. 2020 May 1;27(5):485-488. doi: 10.5551/jat.50435. Epub 2019 Sep 25.
2
Overcoming Challenges With Statin Therapy.他汀类药物治疗面临的挑战及应对策略
J Am Heart Assoc. 2016 Jan 27;5(1):e002497. doi: 10.1161/JAHA.115.002497.
3
MY APPROACH to Managing Statin-Associated Muscle Symptoms.我处理他汀类药物相关肌肉症状的方法。
Trends Cardiovasc Med. 2017 Feb;27(2):160-161. doi: 10.1016/j.tcm.2016.09.007. Epub 2016 Oct 6.
4
Statin Intolerance.他汀不耐受
Rev Cardiovasc Med. 2018;19(S1):S9-S19. doi: 10.3909/ricm19S1S0005.
5
Statin Intolerance From a Clinician's Perspective.临床医生视角下的他汀不耐受
Angiology. 2016 Mar;67(3):205-7. doi: 10.1177/0003319715587416. Epub 2015 May 27.
6
Rosuvastatin in patients with elevated C-reactive protein.
N Engl J Med. 2009 Mar 5;360(10):1038-9; author reply 1041-2.
7
Statin potency associated with incident diabetes in a real-world evaluation.在一项真实世界评估中他汀类药物效力与新发糖尿病的关联。
Evid Based Med. 2014 Apr;19(2):68. doi: 10.1136/eb-2013-101445. Epub 2013 Aug 29.
8
Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.探索他汀不耐受患者的管理：2016年及以后
Curr Vasc Pharmacol. 2016;14(6):523-533. doi: 10.2174/1570161114666160226150028.
9
Addressing key questions with statin therapy.用他汀类药物治疗解决关键问题。
J Fam Pract. 2012 Jun;61(6 Suppl):S34-9.
10
Reinitiation of statins after statin-associated musculoskeletal symptoms: a patient-centered approach.他汀类药物相关肌肉骨骼症状后重新启用他汀类药物：以患者为中心的方法。
Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):243-7. doi: 10.1161/CIRCOUTCOMES.111.000039. Epub 2013 Mar 12.
引用本文的文献
1
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.瑞舒伐他汀与依折麦布固定剂量复方制剂多剂量给药对比瑞舒伐他汀单药治疗中国高胆固醇血症患者（ROSE-CH）：多中心随机对照试验
Lipids Health Dis. 2025 Jul 22;24(1):249. doi: 10.1186/s12944-025-02670-y.
2
Optimizing Long-term Cardiovascular Risk Stratification: Integrating Biomarkers into the Very High-Risk ASCVD Definition in Asian Patients.优化长期心血管风险分层：将生物标志物纳入亚洲患者极高风险动脉粥样硬化性心血管疾病的定义中。
Am J Prev Cardiol. 2025 Mar 16;22:100965. doi: 10.1016/j.ajpc.2025.100965. eCollection 2025 Jun.
3
Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial.依洛尤单抗作为日本受试者稳定他汀类药物治疗辅助药物的随机2期试验结果。 （注：你提供的原文中药物名称有误，正确的是Evolocumab，通用名依洛尤单抗，翻译后的内容按照正确药物名进行了调整，若不调整药物名则翻译为：奥贝西曲匹作为日本受试者稳定他汀类药物治疗辅助药物的随机2期试验结果。） 你可根据实际情况修改。如果是按照你提供的Obicetrapib准确翻译为：奥贝西曲匹作为日本受试者稳定他汀类药物治疗辅助药物的随机2期试验结果。 但Obicetrapib并不是常见的医学药物名称，可能存在信息偏差，你检查下原文是否正确。
J Atheroscler Thromb. 2024 Oct 1;31(10):1386-1397. doi: 10.5551/jat.64828. Epub 2024 Apr 3.
4
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.瑞舒伐他汀与依折麦布单片复方制剂在中国他汀类药物治疗控制不佳的原发性高胆固醇血症患者中的疗效和安全性（ROZEL）：一项随机、双盲、双模拟、阳性药物对照的 III 期临床研究。
Adv Ther. 2023 Dec;40(12):5285-5299. doi: 10.1007/s12325-023-02666-z. Epub 2023 Sep 28.
5
Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review.红曲米改善轻中度高胆固醇血症患者的血脂谱：叙述性综述。
Nutrients. 2023 May 12;15(10):2288. doi: 10.3390/nu15102288.
6
Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study.依洛尤单抗通过降低 2 型糖尿病脂蛋白（a）减轻冠状动脉脂肪组织密度：一项连续随访的 CCTA 研究。
Cardiovasc Diabetol. 2023 May 22;22(1):121. doi: 10.1186/s12933-023-01857-w.
7
Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III.中国缺血性卒中和短暂性脑缺血发作的血脂管理：来自中国国家卒中登记研究 III。
BMJ Open. 2023 Mar 8;13(3):e069465. doi: 10.1136/bmjopen-2022-069465.
8
Impact of Statin Treatment Intensity after Endovascular Revascularization on Lower Extremity Peripheral Artery Disease.血管内血运重建术后他汀类药物治疗强度对下肢外周动脉疾病的影响
Yonsei Med J. 2022 Apr;63(4):333-341. doi: 10.3349/ymj.2022.63.4.333.
9
Causes and outcome of rhabdomyolysis in patients admitted to medical wards in the Prince of Wales Hospital.威尔士亲王医院内科病房收治患者横纹肌溶解症的病因及转归
Ann Transl Med. 2021 Aug;9(16):1329. doi: 10.21037/atm-21-3660.
10
Tackling cardiometabolic risk in the Asia Pacific region.应对亚太地区的心血管代谢风险。
Am J Prev Cardiol. 2020 Nov 8;4:100096. doi: 10.1016/j.ajpc.2020.100096. eCollection 2020 Dec.
本文引用的文献
1
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.贝匹地酸治疗高胆固醇血症及他汀类药物不耐受患者的疗效和安全性。
J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662.
2
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.评估阿托伐他汀+依折麦布固定剂量复方制剂治疗高胆固醇血症的疗效和安全性。
Expert Opin Pharmacother. 2019 Jun;20(8):917-928. doi: 10.1080/14656566.2019.1594776. Epub 2019 Mar 25.
3
A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.一例辛伐他汀诱导的肌肉病，具有 SLCO1B1 遗传易感性，并同时服用利格列汀和甜菊糖。
J Clin Pharm Ther. 2019 Jun;44(3):381-383. doi: 10.1111/jcpt.12805. Epub 2019 Feb 3.
4
Diagnosis and Management of Statin Intolerance.他汀类药物不耐受的诊断和管理。
J Atheroscler Thromb. 2019 Mar 1;26(3):207-215. doi: 10.5551/jat.RV17030. Epub 2019 Jan 19.
5
Associations between vitamin D deficiency, musculoskeletal health, and cardiometabolic risk among community-living people in Taiwan: Age and sex-specific relationship.台湾社区居民中维生素D缺乏、肌肉骨骼健康与心血管代谢风险之间的关联：年龄和性别特异性关系。
Medicine (Baltimore). 2018 Dec;97(52):e13886. doi: 10.1097/MD.0000000000013886.
6
2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.2019 年台湾脂类与动脉硬化学会他汀类药物不耐受专家共识声明。
J Formos Med Assoc. 2019 Oct;118(10):1385-1392. doi: 10.1016/j.jfma.2018.11.017. Epub 2018 Dec 21.
7
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.他汀类药物的安全性及相关不良反应：美国心脏协会的科学声明。
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073.
8
Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy.日本高心血管风险患者开始他汀类药物治疗的治疗模式、他汀类药物不耐受和随后的心血管事件。
Circ J. 2018 Mar 23;82(4):1008-1016. doi: 10.1253/circj.CJ-17-0811. Epub 2017 Dec 23.
9
Statin Responses in Chinese Patients.中国患者的他汀类药物反应
J Atheroscler Thromb. 2018 Feb 1;25(2):199-202. doi: 10.5551/jat.40204. Epub 2017 Jul 21.
10
Racial Differences in the Cholesterol-Lowering Effect of Statin.他汀类药物降胆固醇作用的种族差异。
J Atheroscler Thromb. 2017 Jan 1;24(1):19-25. doi: 10.5551/jat.RV16004. Epub 2016 Oct 12.
Zotero 插件